betamethasone valerate has been researched along with anthralin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonan, P; Cannarozzo, G; Fedi, AM; Lotti, T; Panconesi, E | 1 |
| Bonan, P; Lotti, T; Panconesi, E | 1 |
| Lawrence, CM; Shuster, S | 1 |
| Clement, M; du Vivier, A; Hehir, M; Phillips, H | 1 |
| Ferguson, A; Maden, CJ | 1 |
| Coutts, A; Davies, M; Greaves, M; Misch, K | 1 |
| Kowalzick, L | 1 |
1 review(s) available for betamethasone valerate and anthralin
| Article | Year |
|---|---|
Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis.
Topics: Administration, Topical; Adult; Anthralin; Anti-Inflammatory Agents; Betamethasone Valerate; Calcitriol; Drug Therapy, Combination; Female; Humans; Male; Psoriasis; Ultraviolet Therapy | 2001 |
2 trial(s) available for betamethasone valerate and anthralin
| Article | Year |
|---|---|
The treatment of chronic psoriasis in general practice: a multicentre trial.
Topics: Anthralin; Betamethasone Valerate; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Psoriasis | 1982 |
Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis.
Topics: Administration, Topical; Adult; Anthralin; Anti-Inflammatory Agents; Betamethasone Valerate; Calcitriol; Drug Therapy, Combination; Female; Humans; Male; Psoriasis; Ultraviolet Therapy | 2001 |
5 other study(ies) available for betamethasone valerate and anthralin
| Article | Year |
|---|---|
Antipsoriatic therapies inhibit epidermal plasminogen activator activity.
Topics: Adult; Anthralin; Betamethasone Valerate; Biopsy; Female; Humans; Immunohistochemistry; Male; Middle Aged; Occlusive Dressings; Psoriasis; PUVA Therapy; Skin; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1990 |
Plasminogen activation in psoriasis.
Topics: Adult; Anthralin; Betamethasone Valerate; Biopsy; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged; Plasminogen; Plasminogen Activators; Psoriasis; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1989 |
Mechanism of anthralin inflammation. 2. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum.
Topics: Administration, Topical; Adult; Aged; Anthracenes; Anthralin; Anti-Inflammatory Agents; Betamethasone Valerate; Clobetasol; Dermatitis, Contact; Dose-Response Relationship, Drug; Epidermis; Female; Glucocorticoids; Humans; Hydrocortisone; Male; Middle Aged; Skinfold Thickness | 1985 |
The effect on epidermal DNA synthesis of a combination of topical steroid with either dithranol or tar as used for psoriasis.
Topics: Animals; Anthracenes; Anthralin; Betamethasone; Betamethasone Valerate; Clobetasol; Coal Tar; DNA; Drug Combinations; Epidermis; Male; Mice; Mice, Hairless | 1983 |
Pharmacological studies of anthralin erythema.
Topics: Anthracenes; Anthralin; Aspirin; Betamethasone Valerate; Chlorpheniramine; Erythema; Female; Humans; Indomethacin; Male; Psoriasis; Scopolamine; Skin | 1981 |